Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a high-grade cervical cell change (called CIN2 or CIN3) that has been confirmed by a tissue biopsy
- People with CIN2 who, after discussing watchful waiting with their doctor as recommended by Dutch guidelines, prefer to try imiquimod treatment rather than waiting — those people may be enrolled in the treatment part of the study, while those who prefer watchful waiting may be enrolled in an observation group
- People whose high-grade cervical cell changes have come back or were not fully removed after a previous loop excision procedure (a common treatment to remove abnormal cervical tissue), confirmed by a tissue biopsy
- People aged 18 years or older
Who may not be able to join:
- People who also have high-grade abnormal cell changes in the vagina (not just the cervix)
- People whose reason for their initial cervical examination was a specific type of abnormal smear result (called PAP 4 cytology) (confirm with trial site)
- People who have been diagnosed with a type of pre-cancerous glandular cell change in the cervix called adenocarcinoma in situ
- People who have previously used imiquimod cream to treat cervical cell changes
- People who have previously had cervical cancer
- People currently living with any form of cancer
- People with a weakened immune system, including those living with HIV/AIDS or taking medications that suppress the immune system
- People who are pregnant
- People who are not legally able to give consent for themselves
- People who do not have sufficient knowledge of the Dutch language
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Edith Van Esch, MD, PhD, Catharina Ziekenhuis Eindhoven
Phone: 040 - 239 93 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Confirm association of 'hot signature' immune infiltrates in cHSIL with complete clinical responses to imiquimod; Validate immune biomarker CIBI for imiquimod for predicting complete response in cHSIL; Determine the sensitivity and specificity of the CIBI in cHSIL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.